Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dronabinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 10/20 | 1.00 |
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | GPR18 | Q14330 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronabinol SCHEMBL29390424 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13394311 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL11375978 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL1227386 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13214137 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL24702729 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL3686519 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL4609 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL22705549 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29410178 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 902 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144805-A1 | CANNABIDIOL COMPOSITIONS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2026-05-28 | — | — | US | claimed |
| EP-4727539-A1 | A PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSION | Pico IP, LLC (US) | 2026-04-22 | — | — | EP | claimed |
| US-12558362-B2 | Use of cannabidiol in the treatment of seizures associated with rett syndrome | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2026-02-24 | — | — | US | claimed |
| EP-4181891-B1 | USE OF CANNABIDIOL IN THE TREATMENT OF ABSENCE SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-12-17 | — | — | EP | claimed |
| EP-4181890-B1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-11-26 | — | — | EP | claimed |
| WO-2025213224-A1 | TREATMENT OF KCNT1-RELATED DISORDERS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2025-10-16 | — | — | WO | claimed |
| EP-4181901-B1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-10-15 | — | — | EP | claimed |
| US-20250268924-A1 | PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSION | TERRY MILES J (US) | 2025-08-28 | — | — | US | claimed |
| US-20250198890-A1 | Method and Apparatus for Separating and Concentrating Analytes | BUZZKILL LABS, INC. | 2025-06-19 | — | — | US | claimed |
| EP-4568651-A1 | CANNABIDIOL COMPOSITIONS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS | Jazz Pharmaceuticals Research UK Limited (GB) | 2025-06-18 | — | — | EP | claimed |
| WO-2022017963-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH ENCEPHALITIS | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017948-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017953-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017936-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017951-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED CASK-RELATED DISORDERS | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017926-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017956-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017915-A1 | CANNABIDIOL FOR USE IN THE TREATMENT OF SEIZURES ASSOCIATED WITH BRAIN DAMAGE | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017930-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH JEAVON'S SYNDROME | GW Research Limited (GB) | 2022-01-27 | — | — | WO | claimed |
| CN-113966213-A | Self-emulsifying drug delivery system for delivery of lipophilic compounds | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558362-B2 | Use of cannabidiol in the treatment of seizures associated with rett syndrome | CNR2, CNR1, RET | CNR1 2/4885CNR2 1/4885ABHD12 2173/4885 |
| US-20260144805-A1 | CANNABIDIOL COMPOSITIONS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS | CNR2, CNR1, GAP43 | CNR1 2/4885CNR2 1/4885ABHD12 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.